Precision Cancer Therapy in Rare Cancers

Summary

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Eligibility

Inclusion Criteria:

* ECOG 0-2,
* identified biomarker,
* reasonable biochemistry

Exclusion Criteria:

* ECOG 3-5
* serious other diseases

Conditions2

Interventions3

Related trials

• A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer — Tianjin Medical University Cancer Institute and Hospital
• A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. — Centre Leon Berard
• Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma — Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
• ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Melanoma Metastasized to the Brain and Steroids — Inge Marie Svane
• Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion — Tianjin Medical University Second Hospital
• The Drug Rediscovery Protocol (DRUP Trial) — The Netherlands Cancer Institute
• The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs — Helsinki University Central Hospital

Browse More Trials